JP7160683B2 - 術後癒着の予防及び治療のための方法及び組成物 - Google Patents

術後癒着の予防及び治療のための方法及び組成物 Download PDF

Info

Publication number
JP7160683B2
JP7160683B2 JP2018556332A JP2018556332A JP7160683B2 JP 7160683 B2 JP7160683 B2 JP 7160683B2 JP 2018556332 A JP2018556332 A JP 2018556332A JP 2018556332 A JP2018556332 A JP 2018556332A JP 7160683 B2 JP7160683 B2 JP 7160683B2
Authority
JP
Japan
Prior art keywords
adhesion
adhesions
msln
mesothelial
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018556332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514913A (ja
JP2019514913A5 (enExample
Inventor
サイ，ジョナサン
ファーンホフ，ナサニエル
シンハ，ラフル
リンケビッチ，ユバル
ワイスマン，アービング，エル．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2019514913A publication Critical patent/JP2019514913A/ja
Publication of JP2019514913A5 publication Critical patent/JP2019514913A5/ja
Application granted granted Critical
Publication of JP7160683B2 publication Critical patent/JP7160683B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
JP2018556332A 2016-04-29 2017-05-01 術後癒着の予防及び治療のための方法及び組成物 Active JP7160683B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329666P 2016-04-29 2016-04-29
US62/329,666 2016-04-29
PCT/US2017/030454 WO2017190148A1 (en) 2016-04-29 2017-05-01 Methods and compositions for the prevention and treatment of surgical adhesions

Publications (3)

Publication Number Publication Date
JP2019514913A JP2019514913A (ja) 2019-06-06
JP2019514913A5 JP2019514913A5 (enExample) 2020-05-28
JP7160683B2 true JP7160683B2 (ja) 2022-10-25

Family

ID=60161169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556332A Active JP7160683B2 (ja) 2016-04-29 2017-05-01 術後癒着の予防及び治療のための方法及び組成物

Country Status (9)

Country Link
US (1) US10934355B2 (enExample)
EP (1) EP3448421B1 (enExample)
JP (1) JP7160683B2 (enExample)
CA (1) CA3019841A1 (enExample)
ES (1) ES2903210T3 (enExample)
PL (1) PL3448421T3 (enExample)
PT (1) PT3448421T (enExample)
SI (1) SI3448421T1 (enExample)
WO (1) WO2017190148A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108795867A (zh) * 2018-06-05 2018-11-13 华东理工大学 用于构建结肠癌细胞腹膜转移体外三维模型的方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
US20220125754A1 (en) 2019-01-29 2022-04-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
US20200386772A1 (en) * 2019-06-05 2020-12-10 Mark D. Noar Method For Detecting Bodily Adhesions By Identifying Markers In Circulating Cells
US20230293457A1 (en) * 2020-02-26 2023-09-21 Shanghaitech University Application of disulfiram in coronavirus resistance
CA3202048A1 (en) * 2020-12-14 2022-06-23 Joel ZINDEL Treatment of peritoneal, pleural, and pericardium adhesions
US12440285B2 (en) 2021-01-22 2025-10-14 Cilag Gmbh International Prediction of hemostasis issues based on biomarker monitoring
US20220233135A1 (en) * 2021-01-22 2022-07-28 Ethicon Llc Prediction of adhesions based on biomarker monitoring
US12011163B2 (en) 2021-01-22 2024-06-18 Cilag Gmbh International Prediction of tissue irregularities based on biomarker monitoring
CN113244400B (zh) * 2021-05-21 2022-12-16 华北理工大学 一种C5aRA在制备治疗和/或预防腹腔粘连的产品中的应用
EP4426718A1 (en) * 2021-11-05 2024-09-11 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Modulators of mesothelial ecm movement

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001520201A (ja) 1997-10-16 2001-10-30 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 癒着形成の予防と処置
US20050163781A1 (en) 2002-01-29 2005-07-28 Philippe Koninckx Tissue adhesion formation control
JP2008517943A (ja) 2004-10-25 2008-05-29 ザ ヘンリー エム ジャクソン ファウンデーション Ｈｉｆ−１媒介遺伝子発現を低下させる方法
JP2008532523A (ja) 2005-03-10 2008-08-21 モルフォテック、インク． 抗メソテリン抗体
JP2008542500A (ja) 2005-05-31 2008-11-27 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
JP2011517664A (ja) 2008-03-11 2011-06-16 ファンダシオン デ ラ コミュニダッド バレンシアナ，セントロ デ インヴェスティガシオン プリンシペ フェリペ 低酸素誘導性写因子を阻害する薬学的組成物、ならびに血管新生、発癌、炎症、アポトーシス、および細胞治療の薬学的プロセスの修飾因子
JP2011195574A (ja) 2010-02-25 2011-10-06 Kwansei Gakuin ビスフェノールａ誘導体を含有するｈｉｆ阻害剤
JP2015511987A (ja) 2012-03-16 2015-04-23 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｈｉｆ−１阻害剤の送達のための放出制御製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639468A (en) * 1995-06-07 1997-06-17 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using manoalide and analogs thereof
US6812220B2 (en) 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
US20040131600A1 (en) * 2002-03-11 2004-07-08 Diamond Michael P. Method of preventing adhesions by apoptosis of adhesion peritoneal cells
JP4224586B2 (ja) 2004-04-28 2009-02-18 国立大学法人群馬大学 マクロファージ活性化剤並びにその製造方法及びスクリーニング方法
AU2006279218B2 (en) 2005-08-11 2013-05-02 Adetherapeutics, Inc. Reducing post-operative adhesion formation with intraperitoneal glutamine
WO2008011726A1 (en) 2006-07-27 2008-01-31 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
KR101554753B1 (ko) * 2007-10-01 2015-09-22 브리스톨-마이어스 스큅 컴퍼니 메소텔린에 결합하는 인간 항체 및 이의 용도
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
AU2010230063B2 (en) * 2009-03-24 2015-06-25 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
CA2771336C (en) 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
JP6426693B2 (ja) 2013-03-15 2018-11-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ｃｄ４７薬の処理上有効量を達成するための方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001520201A (ja) 1997-10-16 2001-10-30 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 癒着形成の予防と処置
US20050163781A1 (en) 2002-01-29 2005-07-28 Philippe Koninckx Tissue adhesion formation control
JP2008517943A (ja) 2004-10-25 2008-05-29 ザ ヘンリー エム ジャクソン ファウンデーション Ｈｉｆ−１媒介遺伝子発現を低下させる方法
JP2008532523A (ja) 2005-03-10 2008-08-21 モルフォテック、インク． 抗メソテリン抗体
JP2008542500A (ja) 2005-05-31 2008-11-27 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
JP2011517664A (ja) 2008-03-11 2011-06-16 ファンダシオン デ ラ コミュニダッド バレンシアナ，セントロ デ インヴェスティガシオン プリンシペ フェリペ 低酸素誘導性写因子を阻害する薬学的組成物、ならびに血管新生、発癌、炎症、アポトーシス、および細胞治療の薬学的プロセスの修飾因子
JP2011195574A (ja) 2010-02-25 2011-10-06 Kwansei Gakuin ビスフェノールａ誘導体を含有するｈｉｆ阻害剤
JP2015511987A (ja) 2012-03-16 2015-04-23 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｈｉｆ−１阻害剤の送達のための放出制御製剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Blood Advances, 2019, Vol.3, No.18, pp.2713-2721
International Journal of Surgery, 2011, Vol.9, No.589-594
Mediators of Inflammation, 2012, Vol.2012, Article ID 194723
Sci. Transl. Med., 2018, Vol.10, #eaan6735
Scientific Reports, 2017.10, Vol.7, #13151

Also Published As

Publication number Publication date
JP2019514913A (ja) 2019-06-06
PL3448421T3 (pl) 2022-03-28
US20190048077A1 (en) 2019-02-14
WO2017190148A1 (en) 2017-11-02
SI3448421T1 (sl) 2022-02-28
EP3448421B1 (en) 2021-11-03
CA3019841A1 (en) 2017-11-02
EP3448421A4 (en) 2019-12-25
PT3448421T (pt) 2022-01-14
ES2903210T3 (es) 2022-03-31
US10934355B2 (en) 2021-03-02
EP3448421A1 (en) 2019-03-06

Similar Documents

Publication Publication Date Title
JP7160683B2 (ja) 術後癒着の予防及び治療のための方法及び組成物
Saraswati et al. Identification of a pro-angiogenic functional role for FSP1-positive fibroblast subtype in wound healing
JP6527565B2 (ja) 脱毛障害を処置するための方法
Yuan et al. Chemokine receptor Cxcr4 contributes to kidney fibrosis via multiple effectors
Lv et al. Targeting CD301+ macrophages inhibits endometrial fibrosis and improves pregnancy outcome
WO2018160739A1 (en) Antifibrotic activity of cd47 blockade
US11725056B2 (en) Methods for targeting the immune checkpoint PD1 pathway for treating pulmonary fibrosis
CN115068612B (zh) Drd2抑制剂在制备治疗与肝脏纤维化有关的疾病的药物中的应用
JP2025090705A (ja) 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
US10010585B2 (en) Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma
US10705074B2 (en) Targeting fibroblast invasion for pulmonary fibrosis
McRae et al. Blockade of the G-CSF Receptor Is Protective in a Mouse Model of Renal Ischemia–Reperfusion Injury
CN119074926B (zh) 一种靶向fap的car-t细胞在制备治疗心肌炎慢性期心脏纤维化的药物中的应用
US20230067811A1 (en) Modulating lymphatic vessels in neurological disease
WO2018224614A1 (en) Vegf inhibitors for use for preventing and/or treating acne
He et al. Administration of exogenous fractalkine, a CX3C chemokine, is capable of modulating inflammatory response in cecal ligation and puncture-induced sepsis
US20240115569A1 (en) Methods for blocking her2 signaling for treating pulmonary fibrosis
Wu et al. Eosinophil-derived interleukin-24 compromises epithelial integrity and aggravates airway remodeling in mouse models of allergic asthma
Liebold The interplay between apoptotic cells and macrophages: impact on the phenotype and function of macrophages
CN120678928A (zh) 一种靶向衰老b细胞治疗系统性红斑狼疮的方法和应用
WO2024064879A2 (en) Interferon lambda (ifnl) inhibition in intestinal epithelial cells for treating inflammation
Niroula Lung Stem Cell Heterogeneity in Advanced Cystic Fibrosis
Li et al. Macrophage ITGAV is dispensable for post-infarction remodeling in mice and does not mediate fibronectin responses
Pearmain Investigating the Role of SOX9 in Pulmonary Fibrosis
Watt Dissecting the role of TGFβ in pancreatic ductal adenocarcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221013

R150 Certificate of patent or registration of utility model

Ref document number: 7160683

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250